DADC
ITCI

D.A. Davidson & Co’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

D.A. Davidson & Co’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,298
Closed -$202K – 1181
2018
Q3 		$202K Sell
9,298
-8,175
-47% -$171K ﹤0.01% 1076
2018
Q2 		$309K Buy
17,473
+216
+1% +$4.39K 0.01% 865
2018
Q1 		$363K Buy
+17,257
New +$336K 0.01% 799

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.A. Davidson & Co's ITCI Position: Q4 2018 in Review

D.A. Davidson & Co sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2018, closing a stake of 9,298 shares — an estimated $202K sold.

D.A. Davidson & Co first reported a position in ITCI in Q1 2018 and held it in 3 quarters. The position peaked at $363K in Q1 2018. 127 funds tracked by Wall St. Rank hold ITCI as of Q4 2018.

  • D.A. Davidson & Co reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2018 after selling out during the quarter.
  • D.A. Davidson & Co sold 9,298 Intra-Cellular Therapies Inc. shares in Q4 2018, an estimated $202K.
  • D.A. Davidson & Co first reported a position in Intra-Cellular Therapies Inc. in Q1 2018 and held it in 3 quarters.
  • D.A. Davidson & Co's Intra-Cellular Therapies Inc. position peaked at $363K in Q1 2018.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2018.

Based on D.A. Davidson & Co's 13F filing for Q4 2018, filed 29 Jan 2019.